Home > Cardiology > EHRA 2022 > Other Topics > Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes

Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes

Presented By
Dr Ameenathul Fawzy, Liverpool Heart and Chest Hospital, UK
Presented by
Ameenathul Fawzy Liverpool Heart and Chest Hospital
EHRA 2022
Diabetic patients demonstrated to benefit from sodium-glucose cotransporter-2 (SGLT2) inhibitors beyond the scope of heart failure (HF)-associated outcomes. The risk of HF, overall mortality, cardiac arrest, atrial fibrillation (AF), and ischaemic stroke were reduced in diabetic patients on SGLT2 inhibitors compared with diabetic patients who were not on SGLT2 inhibitors. The use of SGLT2 inhibitors has been associated with improved outcomes in patients with prevalent HF, regardless of the diabetic status of the patient [1]. Moreover, SGLT2 inhibitors have been shown to exert their effect through various cardiometabolic and cardio-renal pathways [2]. The current study aimed to assess the impact of SGLT2 inhibitors on the risk of HF and cardiovascular events in patients with diabetes [3]. Data from the TriNetX database was used to compare 115,749 patients with diabetes who were treated with SGLT2 inhibitors with 11,749 matched participants who wer...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on